Genus Lifesciences has a rich pipeline of future new products. The pipeline is a result of Genus’ rigorous research and development (R&D) program.
With global reach, Genus' R&D plan benefits from the vast intellectual resources and partnerships with foreign companies. Genus actively uses these foreign resources for its testing and development, raw material sourcing and technology planning. Locally in the U.S., chemists, formulation professionals, manufacturing technicians and regulatory specialists also contribute to these efforts.
Genus’ pipeline of new products consists of several NDAs and ANDAs for products in various dosage forms, including tablets, capsules, oral solutions, suspensions, powders, creams and ointments. These new products are at various stages of development, in anticipation of FDA approval, and commercial launch.